

## **NHS Foundation Trust**

Date: 13/04/2016

## FREEDOM OF INFORMATION REQUEST FOI/012693 - Macular degeneration

The total patients treated with the following conditions:

- Wet age-related macular degeneration (AMD)
- Diabetic macular oedema (DMO)
- Macular oedema secondary to retinal vein occlusion, branch (branch RVO)
- Macular oedema secondary to retinal vein occlusion, central (central RVO)
- Myopic choroidal neovascularization (mCNV)

The volume of use of the following treatment options:

- Ranibizumab
- Bevacizamab
- Aflibercept
- · Dexamethasone intravitreal implant
- Fluocinolone acetonide intravitreal implant
- Laser Therapy

Please see below response to your request and please note:-

Bevacizumab (Avastin) is not used in the Trust for any ophthalmic indication.

Our clinical coding process, which captures the actual procedures and diagnoses for our treated patients, uses the ICD10 and OPCS4 coding systems, which do not map to the breakdown of diagnoses and drugs requested, and therefore we cannot provide the full statistics split in this way. Our statistics are therefore the best approximations we can give from the data held electronically by the Trust – greyed areas show where there is no supporting information for the split in diagnosis.

Name of Hospital Trust		The Duc	ley Group	NHS FT								
Name of treatment Hospital if different												
Disease Description and Treatment Option		NUN	IBER OF PA	ATIENTS TR	EATED PER	MONTH (i	f small nui	nbers e.g.	5 or under	suppress	to 5*	
wAMD (Wet Age Related Macular Degeneration)	Mar-15	Apr-15	May-15	Jun-15	Jul-15	Aug-15	Sep-15	Oct-15	Nov-15	Dec-15	Jan-16	Feb-16
Ranibizumab	104	120	114	110	113	87	108	117	89	96	85	74
Bevacizumab	0	0	0	0	0	0	0	0	0	0	0	0
Aflibercept	47	47	38	49	38	47	51	43	43	59	47	49
Disease Description and Treatment Option	nd Treatment Option NUMBER OF PATIENTS TREATED PER MONTH (if small numbers e.g. 5 or under suppress to 5*											
bRVO (Branch Retinal Vein Occlusion)	Mar-15	Apr-15	May-15	Jun-15	Jul-15	Aug-15	Sep-15	Oct-15	Nov-15	Dec-15	Jan-16	Feb-16
Ranibizumab												
Bevacizumab												
Aflibercept												
Dexamethasone intravitreal implant												
Laser therapy treatment for stated condition												
Disease Description and Treatment Option		NUN	IBER OF PA	ATIENTS TR	EATED PER	MONTH (i	f small nui	nbers e.g.	5 or under	suppress	to 5*	
cRVO (Central Retinal Vein Occlusion)	Mar-15	Apr-15	May-15	Jun-15	Jul-15	Aug-15	Sep-15	Oct-15	Nov-15	Dec-15	Jan-16	Feb-16
Ranibizumab												
Bevacizumab												
Aflibercept												
Dexamethasone intravitreal implant												
Laser therapy treatment for stated condition												
Disease Description and Treatment Option		NUN	IBER OF PA	ATIENTS TR	EATED PER	MONTH (i	f small nui	nbers e.g.	5 or under	suppress	to 5*	
DMO (Diabetic Macular Oedema)	Mar-15	Apr-15	May-15	Jun-15	Jul-15	Aug-15	Sep-15	Oct-15	Nov-15	Dec-15	Jan-16	Feb-16
Ranibizumab	52	55	53	61	53	46	54	62	55	67	61	62
Bevacizumab	0	0	0	0	0	0	0	0	0	0	0	0
Aflibercept	0	0	0	0	0	0	0	0	0	0	0	0
Dexamethasone intravitreal implant												
Fluocinolone acetonide intravitreal implant	2	1	0	1	1	0	0	0	1	0	1	0
Laser therapy treatment for stated condition	25	35	11	17	29	26	30	31	31	47	43	30
Disease Description and Treatment Option	Disease Description and Treatment Option NUMBER OF PATIENTS TREATED PER MONTH (if small numbers e.g. 5 or under suppress to 5*											
mCNV (myopic choroidal neovascularization)	Mar-15	Apr-15	May-15	Jun-15	Jul-15	Aug-15	Sep-15	Oct-15	Nov-15	Dec-15	Jan-16	Feb-16
Ranibizumab												
Bevacizumab												
Aflibercept												

Name of treatment Hospital	The Dudley Group NHS FT											
Name of treatment Hospital if different												
Disease Description	Volume of Injections (number of vials used) given by indication by month											
wAMD (Wet Age Related Macular Degeneration	Mar-15	Apr-15	May-15	Jun-15	Jul-15	Aug-15	Sep-15	Oct-15	Nov-15	Dec-15	Jan-16	Feb-16
Ranibizumab	112	124	118	124	123	90	116	121	95	104	90	76
Bevacizumab	0	0	0	0	0	0	0	0	0	0	0	0
Aflibercept	51	48	39	51	40	48	52	45	45	62	48	51
Disease Description	Volume of Injections (number of vials used) given by indication by month											
bRVO (Branch Retinal Vein Occlusion)	Mar-15	Apr-15	May-15	Jun-15	Jul-15	Aug-15	Sep-15	Oct-15	Nov-15	Dec-15	Jan-16	Feb-16
Ranibizumab												
Bevacizumab												
Aflibercept												
Dexamethasone intravitreal implant												
Disease Description	Volume of Injections (number of vials used) given by indication by month											
cRVO (Central Retinal Vein Occlusion)	Mar-15	Apr-15	May-15	Jun-15	Jul-15	Aug-15	Sep-15	Oct-15	Nov-15	Dec-15	Jan-16	Feb-16
Ranibizumab												
Bevacizumab												
Aflibercept												
Dexamethasone intravitreal implant												
Disease Description			Volun	e of Injec	tions (num	ber of vial	s used) giv	en by indi	cation by m	nonth		
DMO (Diabetic Macular Oedema)	Mar-15	Apr-15	May-15	Jun-15	Jul-15	Aug-15	Sep-15	Oct-15	Nov-15	Dec-15	Jan-16	Feb-16
Ranibizumab	64	71	62	76	62	53	62	76	68	83	70	79
Bevacizumab	0	0	0	0	0	0	0	0	0	0	0	0
Aflibercept	0	0	0	0	0	0	0	0	0	0	0	0
Dexamethasone intravitreal implant												
Fluocinolone acetonide intravitreal implant	2	1	0	2	1	0	0	0	1	0	1	0
Disease Description Volume of Injections (number of vials used) given by indication by month												
mCNV (myopic choroidal neovascularization)	Mar-15	Apr-15	May-15	Jun-15	Jul-15	Aug-15	Sep-15	Oct-15	Nov-15	Dec-15	Jan-16	Feb-16
Ranibizumab Lucentis)												
Bevacizumab												
Aflibercept												